Ads
related to: monoclonal antibody and hybridoma technology
Search results
Results from the WOW.Com Content Network
Hybridoma technology is a method for producing large numbers of identical antibodies, also called monoclonal antibodies. This process starts by injecting a mouse (or other mammal) with an antigen that provokes an immune response.
Different from traditional hybridoma technology, the newer technologies use molecular biology techniques to amplify the heavy and light chains of the antibody genes by PCR and produce in either bacterial or mammalian systems with recombinant technology. One of the advantages of the new technologies is applicable to multiple animals, such as ...
The advent of monoclonal antibody technology has made it possible to raise antibodies against specific antigens presented on the surfaces of tumors. [3] Monoclonal antibodies can be acquired in the immune system via passive immunity or active immunity. The advantage of active monoclonal antibody therapy is the fact that the immune system will ...
In contrast to monoclonal antibodies produced by hybridoma technology, which may lose the capacity to produce the desired antibody over time or the antibody may undergo unwanted changes, which affect its functionality, recombinant antibodies produced in phage display maintain high standard of specificity and low immunogenicity. [3] [4]
The principle of monoclonal antibody production, called hybridoma technology, was published in 1975 by Georges Köhler and César Milstein, [30] who were awarded the 1984 Medicine Nobel Prize for their discovery together with Niels Kaj Jerne. [31] Muromonab-CD3 was the first monoclonal antibody to be approved for clinical use in humans, in 1986 ...
HAT selection depicted by a plasmacytoma thymidine kinase mutant fused with a mortal splenic B-cell.. HAT Medium (hypoxanthine-aminopterin-thymidine medium) is a selection medium for mammalian cell culture, which relies on the combination of aminopterin, a drug that acts as a powerful folate metabolism inhibitor by inhibiting dihydrofolate reductase, with hypoxanthine (a purine derivative) and ...
Ads
related to: monoclonal antibody and hybridoma technology